Bio-Rad Laboratories, Inc. (NYSE:BIO) Stake Raised by Blue Trust Inc.

Blue Trust Inc. boosted its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 7.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,132 shares of the medical research company’s stock after buying an additional 76 shares during the period. Blue Trust Inc.’s holdings in Bio-Rad Laboratories were worth $379,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. UMB Bank n.a. raised its holdings in Bio-Rad Laboratories by 140.6% during the 3rd quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after buying an additional 45 shares during the period. Gladius Capital Management LP acquired a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $32,000. Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories during the 3rd quarter worth about $55,000. Livforsakringsbolaget Skandia Omsesidigt raised its holdings in Bio-Rad Laboratories by 281.7% during the 3rd quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 271 shares of the medical research company’s stock worth $91,000 after buying an additional 200 shares during the period. Finally, Quarry LP raised its holdings in Bio-Rad Laboratories by 38.1% during the 3rd quarter. Quarry LP now owns 297 shares of the medical research company’s stock worth $99,000 after buying an additional 82 shares during the period. Institutional investors and hedge funds own 65.24% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have weighed in on the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $481.00 target price on shares of Bio-Rad Laboratories in a research note on Tuesday, January 14th. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Citigroup lifted their target price on Bio-Rad Laboratories from $400.00 to $450.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $394.20.

Bio-Rad Laboratories Trading Up 0.8 %

Shares of NYSE BIO opened at $361.79 on Friday. The stock has a market cap of $10.13 billion, a price-to-earnings ratio of -13.24 and a beta of 0.90. The business has a 50 day simple moving average of $340.27 and a 200 day simple moving average of $335.19. Bio-Rad Laboratories, Inc. has a 52 week low of $262.12 and a 52 week high of $387.99. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.16 by $0.85. The business had revenue of $649.70 million during the quarter, compared to analysts’ expectations of $628.18 million. Bio-Rad Laboratories had a positive return on equity of 3.74% and a negative net margin of 30.18%. The firm’s quarterly revenue was up 2.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.33 EPS. On average, research analysts predict that Bio-Rad Laboratories, Inc. will post 10.33 earnings per share for the current fiscal year.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.